
|Articles|April 30, 2003
Nomogram for BPH progression risk offers aid in clinical decision-making
Chicago-Data from nearly 5,000 participants in the phase III studiesof dutasteride (Avodart) have been used to develop a nomogram for predictingthe probability that an individual patient with BPH will develop acute urinaryretention or require surgical intervention within 2 years and how that riskmay be altered by initiating dutasteride therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











